{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:20:05Z","timestamp":1762082405352,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp and Dohme, Jakarta, Indonesia","award":["ID-8359"],"award-info":[{"award-number":["ID-8359"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Complicated intra-abdominal infections (cIAIs) lead to high morbidity and mortality, especially if poorly managed. However, Indonesia\u2019s microbial pattern and susceptibility data are limited, especially for new antibiotics. Ceftolozane\/tazobactam (C\/T) is reported to be a new potent antibiotic against various pathogens. Thus, we aim to investigate C\/T in vitro activity against clinical isolates from cIAI patients. This prospective cross-sectional study was conducted in three major referral hospitals in Indonesia, including Dr. Cipto Mangunkusumo Hospital (Jakarta), Dr. Kariadi Hospital (Semarang), and Dr. Soetomo Hospital (Surabaya), enrolling those diagnosed with cIAIs. Blood specimens were collected before or after at least 72 h of the last antibiotic administration. Meanwhile, tissue biopsy\/aspirate specimens were collected intraoperatively. These specimens were cultured, followed by a susceptibility test for specific pathogens. The minimum inhibitory concentration (MIC) of isolates was determined according to CLSI M100. Two-hundred-and-eighty-four patients were enrolled from 2019\u20132021. Blood culture was dominated by Gram-positive bacteria (GPB, n = 25, 52.1%), whereas abdominal tissue culture was dominated by Gram-negative bacteria (GNB, n = 268, 79.5%). The three most common organisms were GNB, including E. coli, K. pneumoniae, and P. aeruginosa. C\/T was susceptible in 96.7%, 70.2%, and 94.1% of the E. coli, K. pneumoniae, and P. aeruginosa isolates, respectively. In addition, C\/T also remained active against ESBL Enterobacterales and carbapenem-non-susceptible P. aeruginosa. Overall, C\/T demonstrates a high potency against GNB isolates and can be considered an agent for carbapenem-sparing strategy for cIAI patients as the susceptibility is proven.<\/jats:p>","DOI":"10.3390\/antibiotics12010052","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T02:56:50Z","timestamp":1672282610000},"page":"52","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ceftolozane\/Tazobactam In-Vitro Activity against Clinical Isolates from Complicated Intra-Abdominal Infection Patients in Three Indonesian Referral Hospitals"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9882-2488","authenticated-orcid":false,"given":"Anis","family":"Karuniawati","sequence":"first","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, Universitas Indonesia\u2014Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merry","family":"Ambarwulan","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, Universitas Indonesia\u2014Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selvi Nafisa","family":"Shahab","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, Universitas Indonesia\u2014Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1109-2540","authenticated-orcid":false,"given":"Yefta","family":"Moenadjat","sequence":"additional","affiliation":[{"name":"Department of Surgery, Faculty of Medicine, Universitas Indonesia\u2014Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toar J. M.","family":"Lalisang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Faculty of Medicine, Universitas Indonesia\u2014Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neneng Dewi","family":"Kurniati","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4897-8879","authenticated-orcid":false,"family":"Kuntaman","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky Sumarki","family":"Budipramana","sequence":"additional","affiliation":[{"name":"Division of Digestive Surgery, Department of Surgery, Faculty of Medicine, Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomy","family":"Lesmana","sequence":"additional","affiliation":[{"name":"Division of Digestive Surgery, Department of Surgery, Faculty of Medicine, Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva","family":"Puspitasari","sequence":"additional","affiliation":[{"name":"Dr. Kariadi General Hospital, Semarang 50244, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0379-2328","authenticated-orcid":false,"given":"Erik","family":"Prabowo","sequence":"additional","affiliation":[{"name":"Dr. Kariadi General Hospital, Semarang 50244, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwi Putranti Chitra","family":"Sasmitasari","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Diponegoro University, Semarang 502775, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dian Oktavianti","family":"Putri","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Diponegoro University, Semarang 502775, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7127-8371","authenticated-orcid":false,"given":"Amrilmaen","family":"Badawi","sequence":"additional","affiliation":[{"name":"Global Medical Scientific Affair, Merck Sharp & Dohme (MSD), Jakarta 10220, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(18)30595-6","article-title":"On the road to universal health care in Indonesia, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"392","author":"Mboi","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/IDR.S173867","article-title":"Antibiotic resistance: A rundown of a global crisis","volume":"11","author":"Aslam","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.2147\/IDR.S290835","article-title":"Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health","volume":"ume 13","author":"Majumder","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_4","first-page":"1","article-title":"The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections","volume":"12","author":"Sartelli","year":"2017","journal-title":"World J. Emerg. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"dlab092","DOI":"10.1093\/jacamr\/dlab092","article-title":"Extended-spectrum \u03b2-lactamases: An update on their characteristics, epidemiology and detection","volume":"3","author":"Castanheira","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3934\/microbiol.2018.3.482","article-title":"An overview of the antimicrobial resistance mechanisms of bacteria","volume":"4","author":"Reygaert","year":"2018","journal-title":"AIMS Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13756-017-0208-x","article-title":"The threat of antimicrobial resistance in developing countries: Causes and control strategies","volume":"6","author":"Ayukekbong","year":"2017","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14787210.2018.1447381","article-title":"ISGRI-SITA (Italian Study Group on Resistant Infections of the Societ\u00e0 Italiana Terapia Antinfettiva). Ceftolozane\/tazobactam: Place in therapy","volume":"16","author":"Giacobbe","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_9","unstructured":"IDSA (2022, November 01). IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0. Available online: https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2147\/IDR.S180905","article-title":"Ceftolozane\/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: Current perspectives and place in therapy","volume":"12","author":"Pigrau","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.ijantimicag.2017.01.030","article-title":"Epidemiology and trends in the antibiotic susceptibilities of Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region, 2010\u20132013","volume":"49","author":"Chang","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.7454\/nrjs.v2i2.35","article-title":"Epidemiology of Microorganisms in intraabdominal infection\/complicated intraabdominal infections in six centers of surgical care in Indonesia: A preliminary study","volume":"2","author":"Moenadjat","year":"2017","journal-title":"New Ropanasuri J. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13756-020-00871-x","article-title":"Infections and antimicrobial resistance in intensive care units in lower-middle income countries: A scoping review","volume":"10","author":"Saharman","year":"2021","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Betancur, J.C., De La Cadena, E., Mojica, M.F., Hern\u00e1ndez-G\u00f3mez, C., Correa, A., Radice, M.A., Casta\u00f1eda-M\u00e9ndez, P., Jaime-Villalon, D.A., Gales, A.C., and Munita, J.M. (2022). Comparative In Vitro Activity of Ceftolozane\/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries. Antibiotics, 11.","DOI":"10.3390\/antibiotics11081101"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.amsu.2014.06.005","article-title":"Antibiotic management of complicated intra-abdominal infections in adults: The Asian perspective","volume":"3","author":"Kurup","year":"2014","journal-title":"Ann. Med. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/femsre\/fux013","article-title":"Klebsiella pneumoniae: A major worldwide source and shuttle for antibiotic resistance","volume":"41","author":"Kondratyeva","year":"2017","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jmii.2021.02.001","article-title":"Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan","volume":"55","author":"Yang","year":"2022","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ftz040","DOI":"10.1093\/femspd\/ftz040","article-title":"Imipenem\/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center","volume":"77","author":"Kulengowski","year":"2019","journal-title":"Pathog. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e00465-17","DOI":"10.1128\/AAC.00465-17","article-title":"Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015","volume":"61","author":"Shortridge","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jgar.2019.10.009","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against contemporary (2015\u20132017) Pseudomonas aeruginosa isolates from a global surveillance programme","volume":"21","author":"Shortridge","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Tantisiriwat, W., Buppanharun, J., Ekpanyaskul, C., Onruang, K., Yungyuen, T., Kiratisin, P., and Santiwatanakul, S. (2022). In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against Pseudomonas aeruginosa Infection-Isolates from an Academic Medical Center in Thailand. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060732"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s10096-021-04308-0","article-title":"The ERACE-PA Global Surveillance Program: Ceftolozane\/tazobactam and Ceftazidime\/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa","volume":"40","author":"Gill","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"105959","DOI":"10.1016\/j.ijantimicag.2020.105959","article-title":"Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany","volume":"55","author":"Kresken","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/jac\/dky418","article-title":"In vitro susceptibility of Salmonella enterica serovar Typhi to ceftolozane\/tazobactam","volume":"74","author":"Chan","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_26","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2022). Performance Standards for Antimicrobial Susceptibility Testing, Clinical and Laboratory Standards Institute. [32nd ed.]. CLSI supplement M100."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/1\/52\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:54:43Z","timestamp":1760147683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/1\/52"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["antibiotics12010052"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12010052","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2022,12,28]]}}}